Haisco Pharmaceutical Group (002653.SZ): The new indication for benzenesulfonate pregabalin capsules has been accepted for listing application.

Haisco Pharmaceutical Group (002653.SZ) announced that the company recently received a notice of acceptance from the National Medical Products Administration for a new indication for the innovative drug Pregabalin Sulfate Capsules, which is used to treat adult neuropathic pain. This acceptance is for the market approval application of this drug for this specific indication. Pregabalin Sulfate Capsules is a new third-generation voltage-gated calcium channel modulator developed independently by the company with proprietary intellectual property rights. It works by binding with high affinity to the subunit of the presynaptic membrane of neurons, inhibiting calcium ion influx, reducing the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, thereby relieving central sensitization and exhibiting anti-seizure, analgesic, and anxiolytic activities.